News

Rituxan led Medicare part B drug spending in 2014


 

References

In 2014, Medicare part B drug spending was led by the $1.5 billion cost of Rituxan (rituximab), the Centers for Medicare & Medicaid Services reported.

That made Rituxan – approved to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis – one of six drugs to exceed $1 billion in spending by Medicare part B for the year. Second and third on the list were the macular degeneration/macular edema/diabetic retinopathy drugs Lucentis (ranibizumab) at $1.33 billion and Eylea (aflibercept) at $1.3 billion, according to the Medicare drug spending dashboard.

The other three members of the part B $1-billion club were Neulasta (pegfilgrastim), which prevents chemotherapy-induced neutropenia, at $1.174 billion; the rheumatoid and psoriatic arthritis/Crohn’s disease/ulcerative colitis/ankylosing spondylitis/psoriasis drug Remicade (infliximab) at $1.173 billion; and the chemotherapy drug Avastin (bevacizumab) at $1.06 billion, the CMS said.

Average cost per unit varied widely among the six drugs: Neulasta was $3,200 per unit, followed by Eylea ($960), Rituxan ($690), Lucentis ($390), Remicade ($71), and Avastin ($65).

Part B drug costs in 2014 totaled $21.5 billion for 606 different drug products, with 60% of that total cost going to the 21 drugs with spending over $250 million each, the CMS noted.

rfranki@frontlinemedcom.com

Recommended Reading

Second dose of herpes zoster vaccine beneficial to seniors
MDedge Rheumatology
Oral steroid dose, duration affect diabetes risk for people with RA
MDedge Rheumatology
‘Hot’ joints may predict RA joint damage
MDedge Rheumatology
ACR: Fewer GCA relapses with add-on abatacept
MDedge Rheumatology
ACR: Etanercept during pregnancy doubles the odds of major malformations
MDedge Rheumatology
ACR: The pain of inflammatory disease goes beyond the physical
MDedge Rheumatology
New case of MS possibly related to tocilizumab
MDedge Rheumatology
ACR: Push back when insurance decisions force TNFi change
MDedge Rheumatology
Biologic treatment in pregnancy requires balancing risks
MDedge Rheumatology
Step therapy and biologics: An easier road ahead?
MDedge Rheumatology